<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83529">
  <stage>Registered</stage>
  <submitdate>22/01/2009</submitdate>
  <approvaldate>11/05/2009</approvaldate>
  <actrnumber>ACTRN12609000238279</actrnumber>
  <trial_identification>
    <studytitle>Omega-3 oil and bone health</studytitle>
    <scientifictitle>Plant-based omega-3 fatty acid supplementation, acceptability and efficacy for bone health</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteopenia</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1 year of oral docosohexanoic acid (DHA) 400 mg daily. DHA is of algal origin (i.e. suitable for vegetarians/vegans). All participants will receive oral vitamin D3 1000 IU daily with calcium carbonate 1200 mg daily</interventions>
    <comparator>Oral calcium carbonate 1200 mg with vitamin D3 1000 units daily for 1 year. All participants receive this. Particpants in the placebo group will receive corn oil capsules orally daily for 1 year.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bone mineral density (BMD) as measured by Dual Energy X-ray Absorptiometry (DEXA) at entry into study and after 1 year of participation. DEXA is measured by a form of x-ray machine which uses software to compare absorption of 2 different energies of radiation, thus deriving a Bone Mineral Density value in g/cm2</outcome>
      <timepoint>1 year from commencement of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>change in bone turnover markers as measured by serum N-terminal collagen telopeptide (CTX)</outcome>
      <timepoint>1 year from commencement of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>not applicable</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DEXA BMD T-score between -1.0 and -2.4 (inclusive)

abbreviations as noted above: Bone Mineral density (BMD); Dual Energy X-ray Absorptiometry (DEXA)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>already on antiresorptive agents</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Recruitment through a DEXA bone mineral density testing service. Potential participants with osteopenic BMD values offered information about participation. Participants randomised to treatment (DHA, Ca, vit D) or control (placebo, Ca, vit D). Allocation is concealed by use of numbered containers. An on-site, third party used a random number generator to allocate numbers to either the active or comparator group.</concealment>
    <sequence>Random number generator (computerised sequence generation) used to allocate participants to either
(a) Calcium, vitamin D plus placebo (corn oil capsules); or
(b) Calcium, vitamin D plus DHA
There is no stratification.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2009</anticipatedstartdate>
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/10/2009</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>The Royal Australian College of General Practitioners (RACGP)</primarysponsorname>
    <primarysponsoraddress>RACGP College House
1 Palmerston Crescent
SOUTH MELBOURNE VIC 3205</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Royal Australian College of General Practitioners (RACGP)</fundingname>
      <fundingaddress>RACGP College House
1 Palmerston Crescent
SOUTH MELBOURNE VIC 3205</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Martek Biosciences</sponsorname>
      <sponsoraddress>6480 Dobbin Road, 
Columbia, MD 21045</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Omega-3 oils are known to have benefits for joints, skin and the circulation. There are reasons to believe that they may help improve bone health in people with low bone density. This study aims to examine the safety, effectiveness and acceptability of an omega-3 oil, docosohexanoic acid (DHA) when given for 1 year in combination with calcium and vitamin D.</summary>
    <trialwebsite>None</trialwebsite>
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Adelaide Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Branch
THE UNIVERSITY OF ADELAIDE
SA 5005</ethicaddress>
      <ethicapprovaldate>26/03/2008</ethicapprovaldate>
      <hrec>H-017-2008</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Simon Vanlint</name>
      <address>Discipline of General Practice
University of Adelaide SA 5005</address>
      <phone>+61 8 83034634</phone>
      <fax />
      <email>simon.vanlint@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Simon Vanlint</name>
      <address>Discipline of General Practice
University of Adelaide SA 5005</address>
      <phone>+61883134634</phone>
      <fax />
      <email>simon.vanlint@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Simon Vanlint</name>
      <address>Discipline of General Practice
University of Adelaide SA 5005</address>
      <phone>+61 8 83034634</phone>
      <fax />
      <email>simon.vanlint@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Simon Vanlint</name>
      <address>Discipline of General Practice
University of Adelaide SA 5005</address>
      <phone>+61883134634</phone>
      <fax />
      <email>simon.vanlint@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>